Full Automation of Production Process, Introduction of Sealed System
"Triple CMO Sales by 2025"
[Asia Economy Reporter Lee Gwan-joo] HanAll Biopharma announced on the 31st that it has completed a dedicated production line for hair loss treatment drugs at its factory located in Daejeon and will begin full-scale operation starting from the 1st of next month.
Through this new production line, HanAll plans not only to produce its own sales products (Hairgro tablets, Adamo tablets) but also to expand its contract manufacturing business. Based on improved productivity and quality control capabilities compared to before, the company aims to secure a leading position in the contract manufacturing market and increase contract manufacturing sales of hair loss treatment drugs by more than three times by 2025.
The new production line covers an area of 727.27㎡ and is designed as a dedicated line completely separated from the general pharmaceutical production line, enabling mass production. In particular, by introducing a fully automated system from product manufacturing to packaging, it is expected to shorten process time, increase productivity, and achieve cost reduction effects. The adoption of a sealed production process blocks various external contaminants, allowing thorough quality control.
Flexibility has also been secured for future changes in pharmaceutical manufacturing and quality control standards. Finasteride and dutasteride, similar sex hormone drugs, are recommended to be manufactured separately in some countries such as parts of Europe and the United States due to human safety concerns in the manufacturing process. HanAll explained that through proactive separation of the production line, it has secured stable product manufacturing and delivery capabilities even in the event of future regulatory changes.
Along with securing a leading position in the contract manufacturing market, HanAll plans to enhance the competitiveness of its hair loss treatment products. HanAll’s Hairgro tablets (active ingredient finasteride) ranked 4th in sales in the finasteride 1mg hair loss treatment drug market last year based on pharmaceutical prescription statistics data (UBIST), proving its product strength. Adamo tablets (active ingredient dutasteride) are manufactured in a tablet form differentiated from the existing soft capsule products, and their size has been reduced by about 50% compared to before, which is evaluated to improve storage convenience and medication adherence.
Kim Jang-ho, factory manager of HanAll Biopharma, said, "The domestic hair loss treatment drug market is expected to grow significantly, with an estimated potential patient population of about 10 million including those with latent hair loss conditions. We will actively attract partners through HanAll’s unique strengths such as cost competitiveness, thorough quality control, and stable mass production capabilities.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
